And so to Brent, maybe we start with you, and what are you seeing? How are you feeling that market right there? You talked a little bit about the buoyancy and excitement in the space, but maybe let's double-click a little bit.

I think there are quite a few dynamics that we're monitoring, and it's all pointing toward a lot more activity or heightened activity is gonna continue.

We look at it across a few ways.

You know, one, large med techs are still bought into this strategy of category leadership.

This isn't a novel idea at this point, but many of them are picking a few attractive markets that they're really gonna build franchises within.

And while doing that, they're gonna begin to shed the assets that are not core to their portfolio.

So you got this constant supply that's continuing to hit the market of perfectly good assets that are just coming out of corporate portfolios.

He's always optimistic.

And Brent, from your perspective, I know you get excited about a lot of things, but let's see if you can narrow it down to a few.

Yeah.

I mean, we also are excited about a lot of areas that are pretty hyped up, and you mentioned one of them, which was neuro and the BCI space.

We're generally on the same page with that enormous patient pops of people that need solutions and better options for improved quality of life.

I think another area that's gonna continue to stand out, heart failure.

That continues to just be a huge issue with people cycling through the system and a lot of cost, a lot of issues.

You know, HFpEF is still something that not a lot of good solutions for out there yet.

So I think that's gonna be one of the most fascinating things to watch as we go forward.